4.8 (757) In stock
Signal pathways and precision therapy of small-cell lung cancer
Jinthe VAN LOENHOUT, PhD Student
Frontiers Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors
Non‐coding RNA‐associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma - Khashkhashi Moghadam - 2022 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Frontiers The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
Targeted Therapies and Biomarkers in Small Cell Lung Cancer. - Abstract - Europe PMC
PDF) Auranofin Synergizes with the PARP Inhibitor Olaparib to
Anti-tumor activity of olaparib alone and in combination with
Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells
Cancers, Free Full-Text
PDF) Auranofin Synergizes with the PARP Inhibitor Olaparib to
Elly MARCQ, Postdoctoral Researcher, Doctor of Medicine
Christophe DEBEN, PostDoc Position, PhD
PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway - ScienceDirect
